These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28695148)

  • 1. Pharmacodynamic effects of daclizumab in the intrathecal compartment.
    Komori M; Kosa P; Stein J; Zhao V; Blake A; Cherup J; Sheridan J; Wu T; Bielekova B
    Ann Clin Transl Neurol; 2017 Jul; 4(7):478-490. PubMed ID: 28695148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
    Lin YC; Winokur P; Blake A; Wu T; Romm E; Bielekova B
    Ann Clin Transl Neurol; 2015 May; 2(5):445-55. PubMed ID: 26000318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity.
    Masvekar R; Phillips J; Komori M; Wu T; Bielekova B
    Front Neurosci; 2021; 15():649876. PubMed ID: 33859547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal effects of daclizumab treatment of multiple sclerosis.
    Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
    Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
    Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
    Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Patti F; Chisari CG; D'Amico E; Zappia M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):341-352. PubMed ID: 29363337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.
    Milo R; Stüve O
    Degener Neurol Neuromuscul Dis; 2016; 6():95-109. PubMed ID: 30050372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
    Komori M; Lin YC; Cortese I; Blake A; Ohayon J; Cherup J; Maric D; Kosa P; Wu T; Bielekova B
    Ann Clin Transl Neurol; 2016 Mar; 3(3):166-79. PubMed ID: 27042677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
    PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study.
    Farina G; Magliozzi R; Pitteri M; Reynolds R; Rossi S; Gajofatto A; Benedetti MD; Facchiano F; Monaco S; Calabrese M
    J Neuroinflammation; 2017 Feb; 14(1):40. PubMed ID: 28222766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.
    Lin YC; Winokur P; Blake A; Wu T; Manischewitz J; King LR; Romm E; Golding H; Bielekova B
    Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e196. PubMed ID: 26848487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N; Martin R
    Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.